Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829248 | 1.00 | SLC22A6 (0.37) | SLC22A6GABRR1LMNALDHASRR | |
| SCHEMBL1135986 | 1.00 | SLC22A6 (0.37) | SLC22A6GABRR1LMNALDHASRR | |
| SCHEMBL197015 | 0.82 | — | — | |
| SCHEMBL198166 | 0.82 | — | — | |
| SCHEMBL197016 | 0.82 | — | — | |
| SCHEMBL6928106 | 0.80 | SLC22A6 (0.55) | SLC22A6GABRR1LMNASMN1; SMN2 | |
| SCHEMBL6928966 | 0.80 | SLC22A6 (0.55) | SLC22A6GABRR1LMNASMN1; SMN2 | |
| SCHEMBL6928104 | 0.80 | SLC22A6 (0.55) | SLC22A6GABRR1LMNASMN1; SMN2 | |
| SCHEMBL6928974 | 0.80 | SLC22A6 (0.55) | SLC22A6GABRR1LMNASMN1; SMN2 | |
| SCHEMBL1635793 | 0.80 | SLC22A6 (0.55) | SLC22A6GABRR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117326977-A | Preparation method of 6-cyano-5-hydroxy-3-oxo caproate | 浙江财和生物科技有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4396187-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4367117-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| CN-117326977-A | Preparation method of 6-cyano-5-hydroxy-3-oxo caproate | 浙江财和生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117326977-A | Preparation method of 6-cyano-5-hydroxy-3-oxo caproate | 浙江财和生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117326977-A | Preparation method of 6-cyano-5-hydroxy-3-oxo caproate | 浙江财和生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20070161094-A1 | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives | CODEXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007073875-A1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF HYDROXYKETO COMPOUNDS | IEP GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-7132267-B2 | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters | CODEXIS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1660669-A2 | ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS | Codexis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005026107-A1 | NOVEL PROCESS FOR THE PREPARATION OF TERT-BUTYL 6-CYANO-5-HYDROXY-3-OXOHEXANOATE | BIOCON LIMITED (IN) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005018579-A2 | ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS | CODEXIS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040214297-A1 | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives | CODEXIS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2002096915-A1 | PROCESS FOR PRODUCING OPTICALLY PURE Δ - HYDROXY-Β -KETOESTER DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
| EP-0643689-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF (5R)-1,1-DIMETHYLETHYL 6-CYANO-5-HYDROXY-3-OXO-HEXANOATE | WARNER-LAMBERT COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993007115-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF (5R)-1,1-DIMETHYLETHYL 6-CYANO-5-HYDROXY-3-OXO-HEXANOATE | WARNER-LAMBERT COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144051-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | SLC22A6 3852/4885GABRR1 1911/4885LMNA 2409/4885 |
| US-20230174555-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | SLC22A6 4099/4885GABRR1 2756/4885LMNA 1362/4885 |
| US-12030884-B2 | Pyrazoloquinoline KRAS inhibitors | KRAS, NRAS, HRAS | SLC22A6 4529/4885GABRR1 1678/4885LMNA 2585/4885 |
| US-11939328-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | SLC22A6 3852/4885GABRR1 1911/4885LMNA 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.